Video Experimental Relacionado

Updated: Jul 23, 2026

Simple and Rapid Method to Obtain High-quality Tumor DNA from Clinical-pathological Specimens Using Touch Imprint Cytology

Simple and Rapid Method to Obtain High-quality Tumor DNA from Clinical-pathological Specimens Using Touch Imprint Cytology

Published on: March 21, 2018

Fusión recurrente de los genes de los factores de transcripción TMPRSS2 y ETS en el cáncer de próstata

Scott A Tomlins¹, Daniel R Rhodes, Sven Perner

¹Department of Pathology, University of Michigan Medical School, 1301 Catherine Street, Ann Arbor, MI 48109-0602, USA.

Science (New York, N.Y.)

|October 29, 2005

Resumen

Los investigadores descubrieron fusiones genéticas específicas (TMPRSS2-ERG/ETV1) en el cáncer de próstata, impulsadas por elementos sensibles a los andrógenos. Estas reorganizaciones son comunes e impactan el desarrollo del cáncer, ofreciendo nuevos objetivos diagnósticos y terapéuticos.

Área de la Ciencia:

Genética La genética.
Oncología Oncología.
La bioinformática es la bioinformática.

Sus antecedentes:

Las reorganizaciones cromosómicas recurrentes no se comprenden bien en los carcinomas comunes.
La identificación de las aberraciones oncogénicas es crucial para comprender el desarrollo del cáncer.

Objetivo del estudio:

Para identificar las aberraciones cromosómicas oncogénicas candidatas en el cáncer de próstata utilizando un enfoque de bioinformática.
Para caracterizar las fusiones genéticas recurrentes que involucran factores de transcripción ETS.

Principales métodos:

Análisis bioinformático de la expresión génica atípica.
Fluorescencia en hibridación in situ (FISH) para detectar reordenamientos genéticos.
Experimentos de líneas celulares para investigar la actividad del promotor.

Principales resultados:

ERG y ETV1 fueron identificados como factores de transcripción ETS atípicos en el cáncer de próstata.
Se encontraron fusiones recurrentes de genes de TMPRSS2 (5' UTR) a ERG o ETV1.
Los reordenamientos en ERG o ETV1 estuvieron presentes en 23 de las 29 muestras de cáncer de próstata.
Los elementos promotores TMPRSS2 receptivos a los andrógenos median la sobreexpresión de ETS.

Conclusiones:

Las fusiones de genes TMPRSS2-ERG/ETV1 son comunes en el cáncer de próstata.
Estas reorganizaciones son impulsadas por promotores sensibles a los andrógenos.
Los hallazgos tienen implicaciones para el desarrollo del carcinoma, el diagnóstico molecular y el tratamiento del cáncer de próstata.

Más Videos Relacionados

Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing

Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing

Published on: July 5, 2019

Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis

Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis

Published on: June 27, 2020

Videos de Conceptos Relacionados

Non-LTR Retrotransposons

Non-LTR Retrotransposons

As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...

Metastasis

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...

Cancer-Critical Genes II: Tumor Suppressor Genes

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...

Cancer-Critical Genes II: Tumor Suppressor Genes

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...